Peroxisome Proliferator-Activated Receptor Agonists Increase Nitric Oxide Synthase Expression in Vascular Endothelial Cells
http://www.100md.com
《动脉硬化血栓血管生物学》
From the Department of Molecular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
ABSTRACT
Objective— There has been accumulating evidence demonstrating that activators for peroxisome proliferator-activated receptor (PPAR) have antiinflammatory, antiatherogenic, and vasodilatory effects. We hypothesized that PPAR activators can modulate endothelial nitric oxide synthase (eNOS) expression and its activity in cultured vascular endothelial cells.
Methods and Results— Bovine aortic endothelial cells were treated with the PPAR activator fenofibrate. The amount of eNOS activity and the expression of eNOS protein and its mRNA were determined. Our data show that treatment with fenofibrate for 48 hours resulted in an increase in eNOS activity. Fenofibrate failed to increase eNOS activity within 1 hour. Fenofibrate also increased eNOS protein as well as its mRNA levels. RU486, which has been shown to antagonize PPAR action, inhibited the fenofibrate-induced upregulation of eNOS protein expression. WY14643 and bezafibrate also increased eNOS protein levels, whereas rosiglitazone did not. Transient transfection experiments using human eNOS promoter construct showed that fenofibrate failed to enhance eNOS promoter activity. Actinomycin D studies demonstrated that the half-life of eNOS mRNA increased with fenofibrate treatment.
Conclusions— PPAR activators upregulate eNOS expression, mainly through mechanisms of stabilizing eNOS mRNA. This is a new observation to explain one of the mechanisms of PPAR-mediated cardiovascular protection.
Key Words: atherosclerosis ? endothelium ? nitric oxide ? vascular biology ? vasodilatation
Introduction
Hypolipidemic fibrates are pharmacological compounds that activate peroxisome proliferator-activated receptor (PPAR), a member of the nuclear hormone receptor superfamily.1 These fibrates have been widely used as effective drugs lowering serum triglycerides and low-density lipoprotein cholesterol and raising high-density lipoprotein cholesterol.2 There has been accumulating evidence showing that fibrates have favorable effects of slowing the progression of atherosclerosis and reducing the number of events of coronary heart diseases in high-risk patients.3–5 PPAR is known to be expressed in the liver, which is mainly involved in lipid and lipoprotein metabolism exerted by fibrates.1 In addition, recent studies have shown that PPAR is also expressed in the cardiovascular system, including heart and vascular wall component cells such as vascular endothelial, vascular smooth muscle, and monocyte cells, and performs a direct antiatherogenic and antiinflammatory action.6 Staels et al have shown that PPAR ligands inhibit interleukin (IL)-1-induced expression of IL-6, prostaglandin, and cyclooxygenase 2 in aortic smooth muscle cells.7 These authors further showed that patients receiving fenofibrate, a potent fibrate, had lower plasma C-reactive protein, fibrinogen, and IL-6 concentrations.7 Furthermore, it has been demonstrated that PPAR activators inhibit cytokine-induced vascular cell adhesion molecule-1 (VCAM-1), IL-6 expression,8,9 and thrombin-induced endothelin-1 expression10 in vascular endothelial cells, and inhibit tissue factor expression and activity in monocytes.11
See page 619
Recent reports12,13 have shown that PPAR agonists improve vasodilator function. Playford et al12 clearly demonstrate that fenofibrate significantly improved brachial artery flow-mediated dilatation, but not nitroglycerin-mediated dilatation in patients with type 2 diabetes mellitus. Capell et al13 have also shown that forearm blood flow in response to acetylcholine, nitroprusside, or verapamil was significantly increased after fenofibrate treatment in subjects with hypertriglyceridemia. These clinical studies indicate that endothelium-dependent vasodilatation is improved by the PPAR agonist.
Endothelial nitric oxide (NO) is an important mediator of cardiovascular protection.14 NO is produced from L-arginine by endothelial NO synthase (eNOS), which is shown to possess antiinflammatory and antiatherogenic properties.15 Endothelium-derived NO is mainly responsible for postischemic flow-mediated vasodilatation of peripheral conduit arteries.16 Taken together, we speculated that PPAR agonists act directly on NO production from vascular endothelium, and we thus aimed to investigate the effects of fenofibrate on eNOS activity and its expression in cultured vascular endothelial cells.
Methods
Cell Culture and Materials
Bovine aortic endothelial cells (BAECs; Cell Systems) were grown in DMEM with 10% FBS (JRH Biosciences). Cells from 3 to 5 passages were used in the experiments. Fenofibrate was purchased from Sigma Chemical. Bezafibrate was obtained from Wako Chemical, rosiglitazone from Mitsubishi Pharmaceutical, and WY14643 and RU486 from Biomol. Mouse anti-eNOS antibody and mouse anti-?-actin antibody were purchased from Biomol and ICN Biomedicals, respectively. Horseradish peroxidase–conjugated sheep anti-mouse IgG antibody and -arginine were from Amersham.
eNOS Activity Assay
BAECs were grown in the growth medium on 35-mm collagen-coated dishes until subconfluency. After the culture medium was changed to DMEM with 2% FBS for 24 hours, the cells were treated with test compounds or vehicle (0.1% dimethylsulfoxide) for the indicated period. The cells were harvested and homogenized in PBS containing 1 mmol/L EDTA. eNOS activity was measured as the conversion of radiolabeled L-arginine to L-citrulline using NOS Quantitative Assay Kit (Bioxytech, OXIS International). Incubation in the presence of the eNOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) (1 mmol/L) served as negative controls.
Western Blot Analysis
BAECs grown on 35-mm collagen-coated dishes were treated for test compounds or vehicle in DMEM with 2% FBS for the indicated periods. The cells were scraped in lysis buffer with protease inhibitor cocktail tablet (complete Mini; Roche), 200 μmol/L NaF, 200 μmol/L Na3VO4, 1 μmol/L dithiothreitol, and 200 μmol/L phenylmethylsulfonyl fluoride, and then sonicated briefly. After being boiled for 2 minutes, the samples were centrifuged at 15 000 rpm for 5 minutes and then analyzed by SDS-PAGE. The gels were transferred to polyvinylidine difluoride (PVDF) membranes (Bio-Rad) by blotting at 100 V for 2 hours. After incubation for 1 hour in blocking buffer (5% skim milk powder in TBS-T ), the membranes were incubated with primary antibody overnight at 4°C. After washing with TBS-T, the membranes were incubated with second antibody at room temperature for 1 hour. The membranes were then washed with TBS-T, and signals were visualized by chemiluminescence (Amersham) and exposed to x-ray films (Fujifilm).
Northern Blot Analysis
BAECs grown on 10-cm collagen-coated dishes were treated for test compounds or vehicle in DMEM with 2% FBS for the indicated periods. Total RNA extracted by the acid guanidinium thiocyanate-phenol-chloroform method was electrophoresed in 1% agarose-5% formaldehyde gels. The gels were transferred to nylon membranes (Hybond N+, Amersham), and the membranes were hybridized at 68°C with 32P-labeled bovine eNOS cDNA probe or GAPDH cDNA probe using Perfect hybridization buffer (Toyobo). After the hybridization, the filters were washed two times in 2xSSC and 0.1% SDS at 60°C for 10 minutes, followed by washing in 0.1xSSC and 0.1% SDS at 60°C for 30 minutes. The membranes were then dried and exposed to x-ray films.
Transient Transfection and Luciferase Reporter Assay
To examine the effect of test compounds on eNOS promoter activity, BAECs were transiently transfected with an eNOS reporter construct. The eNOS reporter consists of 5'-flanking region (-1600 to +26) of the human eNOS gene and firefly luciferase. BAECs on 24-well collagen-coated dishes were transfected with the reporter plasmids (1 μg) together with seapansy luciferase control plasmid (0.05 μg; Tokyo Beanet) using SuperFect Transfection Reagent (QIAGEN). Two hours after the transfection, the cells were treated for 24 hours with test compounds or vehicle. The cell lysates were assayed for each luciferase activity in Lumat LB9501 luminometer (Berthold System).
eNOS mRNA Stability Assay
Subconfluent BAECs on 10-cm collagen coated dishes were treated for the indicated periods with fenofibrate or vehicle in the presence of 2.5 μg/mL actinomycin D in DMEM with 2% FBS. Northern blot analyses for eNOS mRNA and GAPDH mRNA were performed, as described.
Statistics
All values represent mean±SD. The data were analyzed by ANOVA, and the Bonferroni method was used to estimate the level of significance of differences between means. P<0.05 was considered statistically significant.
Results
Effects of Fenofibrate on eNOS Activity
First, we investigated whether fenofibrate alters eNOS enzymatic activity in lysates of BAECs. As shown in Figure 1A, fenofibrate treatment for 48 hours increased eNOS activity in a concentration-dependent manner: At concentrations of 10 μmol/L or more, fenofibrate treatment caused a significant increase in eNOS activity. There was no increase in eNOS activity by fenofibrate treatment within 1 hour, and the fenofibrate-stimulated induction of eNOS activity was observed 24 hours after stimulation (Figure 1B).
Figure 1. Fenofibrate increases eNOS activity in BAECs. A, BAECs were treated for 48 hours with increasing concentrations of fenofibrate. B, BAECs were treated for the indicated periods with 50 μmol/L fenofibrate. Cell lysates were harvested for determination of eNOS activity. Data are mean±SD in three experiments. cont indicates control; Feno, fenofibrate. *P<0.005, **P<0.0001 vs control, by ANOVA.
Effects of Fenofibrate on eNOS Protein Expression
Treatment of BAECs with fenofibrate for 48 hours demonstrated a concentration-dependent increase in eNOS protein levels as measured by Western blot analysis (Figure 2 A and 2B). Densitometric analysis indicated that there was a significant increase in eNOS to ?-actin ratios after fenofibrate treatment at concentrations of 10 and 50 μmol/L. The significant increase in eNOS protein levels was observed 12 hours after treatment and lasted for 48 hours (Figure 2C and 2D).
Figure 2. Fenofibrate increases eNOS protein levels in BAECs, as demonstrated by Western blot analyses. A and B, BAECs were treated for 48 hours with increasing concentrations of fenofibrate. C and D, BAECs were treated for the indicated period with 50 μmol/L fenofibrate. Representative blots are illustrated in A and C. The densitometric readings as percent control of eNOS relative to ?-actin levels are shown in B and D. Data are mean±SD in three experiments. cont indicates control; Feno, fenofibrate. *P<0.005, **P<0.0001 vs control, by ANOVA.
As shown in Figure 3, treatment of BAECs with 50 μmol/L bezafibrate as well as 50 μmol/L WY14643 for 48 hours also caused a significant increase in eNOS protein levels, whereas 50 μmol/L rosiglitazone elicited no change. The simultaneous treatment of BAECs with RU486 (10 μmol/L) resulted in the inhibition of fenofibrate (50 μmol/L)-induced increase in eNOS protein levels (Figure 4).
Figure 3. Fenofibrate, bezafibrate, and WY14643, but not rosiglitazone, increase eNOS protein levels in BAECs, as demonstrated by Western blot analyses. BAECs were treated for 48 hours with fenofibrate (10 or 50 μmol/L), bezafibrate (10 or 50 μmol/L), rosiglitazone (50 μmol/L), or WY14643 (50 μmol/L). Representative blots are illustrated in A. The densitometric readings as percent control of eNOS relative to ?-actin levels are shown in B. Data are mean±SD in three experiments. cont indicates control; Feno, fenofibrate; Beza, bezafibrate; Rosi, rosiglitazone; WY, WY14643. *P<0.005, **P<0.0001 vs control, by ANOVA.
Figure 4. RU486 antagonizes fenofibrate-induced increase in eNOS protein levels in BAECs, as demonstrated by Western blot analyses. BAECs were treated for 48 hours with 50 μmol/L fenofibrate together with or without 10 μmol/L RU486. Representative blots are illustrated in A. The densitometric readings as percent control of eNOS relative to ?-actin levels are shown in B. Data are mean±SD in three experiments. cont indicates control; Feno, fenofibrate. *P<0.0001 vs Feno alone, by ANOVA.
Effects of Fenofibrate on eNOS mRNA Expression
Northern blot analysis demonstrated that treatment with fenofibrate for 24 hours resulted in a concentration-dependent increase in eNOS mRNA levels (Figure 5A). Densitometric scan revealed that eNOS mRNA relative to GAPDH mRNA significantly increased at concentrations of 5 μmol/L or more: it reached 1.9-fold by the treatment with 50 μmol/L fenofibrate (Figure 5B). Significant increase in eNOS mRNA levels was observed after 6 hours, and subsequently there was a gradual decrease of eNOS mRNA levels (Figure 5C and 5D).
Figure 5. Fenofibrate increases eNOS mRNA levels in BAECs, as demonstrated by Northern blot analyses. A and B, BAECs were treated for 24 hours with increasing concentrations of fenofibrate. C and D, BAECs were treated for the indicated periods with 50 μmol/L fenofibrate. Representative blots are illustrated in A and C. The densitometric readings as percent control of eNOS mRNA relative to GAPDH mRNA levels are shown in B and D. Data are mean±SD in three experiments. cont indicates control; Feno, fenofibrate. *P<0.0001 vs control, by ANOVA.
Effects of Fenofibrate on eNOS Promoter Activity and eNOS mRNA Stability
To investigate whether or not fenofibrate increases eNOS mRNA levels at transcription levels, we performed transient transfection assay using eNOS promoter fragment (Figure 6A). PMA, used as a positive control, increased eNOS promoter activity by 4.0-fold compared with that in unstimulated cells. Fenofibrate failed to increase eNOS promoter activity.
Figure 6. Fenofibrate fails to increase eNOS promoter activity (A). It increases half-life of eNOS mRNA (B). A, Two hours after transfection with -1600 to +26 of human eNOS gene-based luciferase reporter construct, BAECs were treated for 24 hours with 50 μmol/L fenofibrate or 100 nM PMA. Luciferase activity was adjusted for control reporter activity. Data are mean±SD in triplicated assays typical of three separate experiments. B, BAECs were treated with or without 50 μmol/L fenofibrate up to 15 hours in the presence of actinomycin D (2.5 μg/mL). Northern blot analyses were performed. The densitometric readings as percent of initial eNOS mRNA relative to GAPDH mRNA levels are shown. Data are mean±SD in three experiments. cont indicates control; Feno, fenofibrate. *P<0.001, **P<0.0005 vs control, by ANOVA.
Next, we studied the effects of fenofibrate on eNOS mRNA stability after stopping the transcription with actinomycin D. The half-life of eNOS mRNA relative to GAPDH mRNA levels was about 24 hours in control, and it increased to about 110 hours by treatment with 50 μmol/L fenofibrate (Figure 6B).
Discussion
The PPAR activators fibrates are shown to slow atherosclerosis progression and reduce the number of events of coronary heart diseases.3–5 Such effects may be attributable at least in part to their effects on lipoprotein abnormalities, which are mainly exerted by PPAR expressed in the liver. Several studies9,10,17,18 have demonstrated that PPAR is also expressed in vascular endothelial cells. Recently, direct roles of fibrates in vascular endothelial cells have become evident, clarifying the inhibitory effects of the PPAR activators on the expression of VCAM-1, IL-6, and endothelin-1.8–10 IL-6 is known to control macrophage and T cell activation as well as vascular smooth muscle cell proliferation,19,20 and has been detected in human and rabbit atherosclerotic regions.21,22 VCAM-1 plays an important role in mediating mononuclear leukocyte-selective adhesion to vascular endothelium, which may be involved in the initial steps of atherosclerotic process.23 Endothelin-1 is a potent vasoconstrictor peptide and inducer of vascular smooth muscle cell proliferation.24,25 Thus, all these molecules are known to be involved in the atherosclerotic process, and suppression of their expression may also be attributable partly to the antiatherogenic effects of PPAR activators.
Endothelium-derived NO is a potent chemical mediator with antiatherogenic properties, such as stimulation of vasorelaxation and repression of endothelial leukocyte adhesion molecules, platelet aggregation, and smooth muscle cell proliferation.16,26,27 To date, it is unknown whether PPAR activators can directly modulate eNOS activity and its expression, which mediates endothelial NO production. Our study clearly demonstrates that fenofibrate upregulated eNOS protein levels in cultured vascular endothelial cells. This effect of fenofibrate was observed at concentrations at 10 μmol/L or more, which are near to plasma concentrations of its active metabolite fenofibric acid found in humans administered.28 In addition, such concentrations corresponded closely to the range of activation of PPAR by fenofibrate, although this compound can also activate PPAR with approximately 10-fold lower selectivity than PPAR.29,30 WY14643, a selective PPAR activator,30 and bezafibrate, a hypolipidemic drug that potentially activates three types of PPAR (PPAR, -, and -),30,31 also increased eNOS protein expression. By contrast, rosiglitazone, a specific ligand for PPAR,32 failed to increase eNOS protein levels. In addition, RU486, which has been shown to have a potential to antagonize the inhibitory effect of PPAR on IL-6 production probably via interference with nuclear translocation of PPAR,33 inhibited the fenofibrate-induced upregulation of eNOS expression. The sum total of these observations suggests that fenofibrate-induced upregulation of eNOS protein expression may be mediated through PPAR.
We demonstrated that eNOS mRNA levels increased after the treatment of vascular endothelial cells with fenofibrate, which is parallel with the increase in protein levels and enzymatic activity of eNOS. Thus, the effect of fenofibrate is primarily caused by the elevation of steady state levels of eNOS mRNA. It is known that eNOS activity is regulated by genomic mechanisms as well as nongenomic mechanisms. The latter mechanisms imply activation by phosphorylation of eNOS by the protein kinase Akt/protein kinase B (PKB).34,35 In our experiments, eNOS activity could not increase so rapidly (1 hour) after the fenofibrate treatment, indicating that PPAR does not exert posttranslational modification of eNOS activity. This seems to be in contrast with cases of other nuclear receptors such as estrogen receptor36 and glucocorticoid receptor,37 both of which are capable of stimulating phosphatidylinositol 3-kinase (PI3-K) and Akt/PKB. Simoncini et al36 have shown that WY14643 failed to activate PI3-K activity in PPAR immunoprecipitates. However, it is not possible from our results to determine the effect of fenofibrate on phosphorylation of eNOS. Further studies will be needed to clarify this issue.
Analysis of the human eNOS promoter sequence (-1600 to +22 nucleotides) did not reveal the presence of any discernible PPAR response elements,38 suggesting that PPAR may not directly interact with eNOS promoter region. In fact, transient transfection experiments of the eNOS promoter construct showed that fenofibrate could not elevate its promoter activity. mRNA stability assays using the transcriptional inhibitor actinomycin D revealed that fenofibrate increased the half-life of eNOS mRNA, suggesting that fenofibrate performs the novel action of stabilizing mRNA for eNOS. The precise mechanism of fenofibrate-mediated mRNA stabilization is unknown. In this relation, it has been postulated that estrogens stabilize mammalian mRNAs, requiring specific sequences of the mRNA and the presence of estrogen receptor.39 Similar mechanisms may operate in the stabilizing effect of PPAR on eNOS mRNA.
The PPAR activators glitazones are also shown to improve vascular and endothelial function.40 In our experiments, rosiglitazone failed to upregulate eNOS protein levels. Recently, PPAR ligands have been shown to increase NO release from vascular endothelial cells without altering eNOS mRNA levels, probably through a transcriptional mechanism unrelated to eNOS expression.41 Together with these results, our findings show that PPAR and PPAR may increase NO production in endothelium by different mechanisms.
Tabernero et al42 have shown that fenofibrate improves NO-mediated vasodilatation in the aorta and in the mesenteric vascular bed, which cannot be explained by an increase in eNOS expression. In addition, Deplanque et al43 have demonstrated that fenofibrate reduces susceptibility to stroke in apolipoprotein E-deficient mice and decreases infarct size volume in mice. This neuroprotective effect is partly associated with an improvement in middle cerebral artery sensitivity to endothelium-dependent relaxation, which is unrelated to an increase in eNOS expression. Thus, the effects of fenofibrate on eNOS expression in these mouse models are not the same as those observed in our study. These mouse models may not always reflect the direct effect of fenofibrate on endothelial cells.
Diabetes Atherosclerosis Intervention Study (DAIS)5 as well as Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)3,4 suggest that treatment with fenofibrate or bezafibrate reduces the progression of coronary artery disease. It is thought that such effects are related, at least partly, to the correction of lipoprotein abnormalities. Mice with targeted disruption of eNOS revealed that eNOS is a very important molecule that plays beneficial roles in cardiovascular disease.44 Therefore, upregulation of eNOS expression and its activity by fenofibrate as well as bezafibrate may also attribute to these drugs a mediated inhibition of the atherosclerosis progression. The expression of eNOS and endothelin-1 is known to be coordinately regulated in diverse pharmacological and experimental conditions.45,46 Since PPAR agonists have the potential to inhibit endothelin-1 expression,10 our results may give another example of the coordinated regulation between eNOS and endothelin-1 systems. These effects might explain the vasodilator function of PPAR agonists.13,14
Acknowledgments
We thank Dr Yasuko Kureishi (Mie University) for providing us bovine eNOS cDNA probe and Dr Masafumi Nakayama (Kumamoto University) for providing human eNOS reporter construct. This work was supported in part by a grant-in-aid for scientific research from the Ministry of Education, Science, Sports, and Culture of Japan (to S. Kasayama).
References
Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000; 405: 421–424.
Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998; 98: 2088–2093.
Ericsson CG, Nilsson J, Grip L, Svane B, Hamsten A. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial ). Am J Cardiol. 1997; 80: 1125–1129.
Ruotolo G, Ericsson CG, Tettamanti C, Karpe F, Grip L, Svane B, Nilsson J, de Faire U, Hamsten A. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol. 1998; 32: 1648–1656.
Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001; 357: 905–910.
Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-B and AP-1. J Biol Chem. 1999; 274: 32048–32054.
Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPAR but not by PPAR activators. Nature. 1998; 393: 790–793.
Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPAR activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999; 99: 3125–3131.
Xu X, Otsuki M, Saito H, Sumitani S, Yamamoto H, Asanuma N, Kouhara H, Kasayama S. PPAR and GR differentially down-regulate the expression of nuclear factor-B-responsive genes in vascular endothelial cells. Endocrinology. 2001; 142: 3332–3339.
Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, Staels B. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 1999; 85: 394–402.
Neve BP, Corseaux D, Chinetti G, Zawadzki C, Fruchart JC, Duriez P, Staels B, Jude B. PPAR agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation. 2001; 103: 207–212.
Playford DA, Watts GF, Best JD, Burke V. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol. 2002; 90: 1254–1257.
Capell WH, DeSouza CA, Poirier P, Bell ML, Stauffer BL, Weil KM, Hernandez TL, Eckel RH. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2003; 23: 307–313.
Loscalzo J. Nitric oxide and vascular tone. N Engl J Med. 1995; 333: 251–253.
De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr., Shin WS, Liao JK. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995; 96: 60–68.
Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Luscher TF. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995; 92: 1314–1319.
Inoue I, Shino K, Noji S, Awata T, Katayama S. Expression of peroxisome proliferator-activated receptor (PPAR) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun. 1998; 246: 370–374.
Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem. 1999; 274: 9116–9121.
Akira S, Kishimoto T. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Review. 1992; 127: 25–50.
Nabata T, Morimoto S, Koh E, Shiraishi T, Ogihara T. Interleukin-6 stimulates c-myc expression and proliferation of cultured vascular smooth muscle cells. Biochem Int. 1990; 20: 445–454.
Ikeda U, Ikeda M, Seino Y, Takahashi M, Kano S, Shimada K. Interleukin 6 gene transcripts are expressed in atherosclerotic legions of genetically hyperlipidemic rabbits. Atherosclerosis. 1992; 92: 213–218.
Seino Y, Ikeda U, Ikeda M, Yamamoto K, Misawa Y, Hasegawa T, Kano S, Shimada K. Interleukin 6 gene transcripts are expressed in human atherosclerotic legions. Cytokine. 1994; 6: 87–91.
Bevilacqua MP, Nelson RM, Mannori G, Cecconi O. Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med. 1994; 45: 361–378.
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 323: 411–415.
Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett. 1988; 238: 249–252.
Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993; 329: 2002–2012.
Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, Kleinert H. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension. 1994; 23: 1121–1131.
Adkins JC, Faulds D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs. 1997; 54: 615–633.
Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B, Auwerx J. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest. 1995; 96: 741–750.
Krey G, Braissant O, L’Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 1997; 11: 779–791.
Brown PJ, Winegar DA, Plunket KD, Moore LB, Lewis MC, Wilson JG, Sundseth SS, Koble CS, Wu Z, Chapman JM, Lehmann JM, Kliewer SA, Willson TM. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPAR agonist with potent lipid-lowering activity. J Med Chem. 1999; 42: 3785–3788.
Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ, Haigh D, Hindley RM, Holder JC, Kallender H, Latter AJ, Lawrie KW, Mossakowska D, Murphy GJ, Roxbee Cox L, Smith SA. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther. 1998; 284: 751–759.
Xu X, Otsuki M, Sumitani S, Saito H, Kouhara H, Kasayama S. RU486 antagonizes the inhibitory effect of peroxisome proliferators-activated receptor on interleukin-6 production in vascular endothelial cells. J Steroid Biochem Molec Biol. 2002; 81: 141–146.
Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999; 399: 597–601.
Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999; 399: 601–605.
Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000; 407: 538–541.
Hafezi-Moghadam A, Simoncini T, Yang E, Limbourg FP, Plumier JC, Rebsamen MC, Hsieh CM, Chui DS, Thomas KL, Prorock AJ, Laubach VE, Moskowitz MA, French BA, Ley K, Liao JK. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nature Med. 2002; 8: 473–479.
Zhang R, Min W, Sessa WC. Functional analysis of the human endothelial nitric oxide synthase promoter. Sp1 and GATA factors are necessary for basal transcription in endothelial cells. J Biol Chem. 1995; 270: 15320–15326.
Dodson RE, Shapiro DJ. An estrogen-inducible protein binds specifically to a sequence in the 3' untranslated region of estrogen-stabilized vitellogenin mRNA. Mol Cell Biol. 1994; 14: 3130–3138.
Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in zucker fatty rats. Diabetes. 1999; 48: 1448–1453.
Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol. 2003; 23: 52–57.
Tabernero A, Schoonjans K, Jesel L, Carpusca I, Auwerx J, Andriantsitohaina R. Activation of the peroxisome proliferator-activated receptor protects against myocardial ischaemic injury and improves endothelial vasodilatation. BMC Pharmacol. 2002; 2: 10.
Deplanque D, Gele P, Petrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, Cecchelli R, Staels B, Duriez P, Bordet R. Peroxisome proliferator-activated receptor- activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci. 2003; 16: 6264–6271.
Moroi M, Zhang L, Yasuda T, Virmani R, Gold HK, Fishman MC, Huang PL. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest. 1998; 101: 1225–1232.
Flowers MA, Wang Y, Stewart RJ, Patel B, Marsden PA. Reciprocal regulation of endothelin-1 and endothelial constitutive NOS in proliferating endothelial cells. Am J Physiol. 1995; 269: H1988–H1997.
Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998; 101: 2711–2719.(Kayoko Goya; Satoru Sumit)
ABSTRACT
Objective— There has been accumulating evidence demonstrating that activators for peroxisome proliferator-activated receptor (PPAR) have antiinflammatory, antiatherogenic, and vasodilatory effects. We hypothesized that PPAR activators can modulate endothelial nitric oxide synthase (eNOS) expression and its activity in cultured vascular endothelial cells.
Methods and Results— Bovine aortic endothelial cells were treated with the PPAR activator fenofibrate. The amount of eNOS activity and the expression of eNOS protein and its mRNA were determined. Our data show that treatment with fenofibrate for 48 hours resulted in an increase in eNOS activity. Fenofibrate failed to increase eNOS activity within 1 hour. Fenofibrate also increased eNOS protein as well as its mRNA levels. RU486, which has been shown to antagonize PPAR action, inhibited the fenofibrate-induced upregulation of eNOS protein expression. WY14643 and bezafibrate also increased eNOS protein levels, whereas rosiglitazone did not. Transient transfection experiments using human eNOS promoter construct showed that fenofibrate failed to enhance eNOS promoter activity. Actinomycin D studies demonstrated that the half-life of eNOS mRNA increased with fenofibrate treatment.
Conclusions— PPAR activators upregulate eNOS expression, mainly through mechanisms of stabilizing eNOS mRNA. This is a new observation to explain one of the mechanisms of PPAR-mediated cardiovascular protection.
Key Words: atherosclerosis ? endothelium ? nitric oxide ? vascular biology ? vasodilatation
Introduction
Hypolipidemic fibrates are pharmacological compounds that activate peroxisome proliferator-activated receptor (PPAR), a member of the nuclear hormone receptor superfamily.1 These fibrates have been widely used as effective drugs lowering serum triglycerides and low-density lipoprotein cholesterol and raising high-density lipoprotein cholesterol.2 There has been accumulating evidence showing that fibrates have favorable effects of slowing the progression of atherosclerosis and reducing the number of events of coronary heart diseases in high-risk patients.3–5 PPAR is known to be expressed in the liver, which is mainly involved in lipid and lipoprotein metabolism exerted by fibrates.1 In addition, recent studies have shown that PPAR is also expressed in the cardiovascular system, including heart and vascular wall component cells such as vascular endothelial, vascular smooth muscle, and monocyte cells, and performs a direct antiatherogenic and antiinflammatory action.6 Staels et al have shown that PPAR ligands inhibit interleukin (IL)-1-induced expression of IL-6, prostaglandin, and cyclooxygenase 2 in aortic smooth muscle cells.7 These authors further showed that patients receiving fenofibrate, a potent fibrate, had lower plasma C-reactive protein, fibrinogen, and IL-6 concentrations.7 Furthermore, it has been demonstrated that PPAR activators inhibit cytokine-induced vascular cell adhesion molecule-1 (VCAM-1), IL-6 expression,8,9 and thrombin-induced endothelin-1 expression10 in vascular endothelial cells, and inhibit tissue factor expression and activity in monocytes.11
See page 619
Recent reports12,13 have shown that PPAR agonists improve vasodilator function. Playford et al12 clearly demonstrate that fenofibrate significantly improved brachial artery flow-mediated dilatation, but not nitroglycerin-mediated dilatation in patients with type 2 diabetes mellitus. Capell et al13 have also shown that forearm blood flow in response to acetylcholine, nitroprusside, or verapamil was significantly increased after fenofibrate treatment in subjects with hypertriglyceridemia. These clinical studies indicate that endothelium-dependent vasodilatation is improved by the PPAR agonist.
Endothelial nitric oxide (NO) is an important mediator of cardiovascular protection.14 NO is produced from L-arginine by endothelial NO synthase (eNOS), which is shown to possess antiinflammatory and antiatherogenic properties.15 Endothelium-derived NO is mainly responsible for postischemic flow-mediated vasodilatation of peripheral conduit arteries.16 Taken together, we speculated that PPAR agonists act directly on NO production from vascular endothelium, and we thus aimed to investigate the effects of fenofibrate on eNOS activity and its expression in cultured vascular endothelial cells.
Methods
Cell Culture and Materials
Bovine aortic endothelial cells (BAECs; Cell Systems) were grown in DMEM with 10% FBS (JRH Biosciences). Cells from 3 to 5 passages were used in the experiments. Fenofibrate was purchased from Sigma Chemical. Bezafibrate was obtained from Wako Chemical, rosiglitazone from Mitsubishi Pharmaceutical, and WY14643 and RU486 from Biomol. Mouse anti-eNOS antibody and mouse anti-?-actin antibody were purchased from Biomol and ICN Biomedicals, respectively. Horseradish peroxidase–conjugated sheep anti-mouse IgG antibody and -arginine were from Amersham.
eNOS Activity Assay
BAECs were grown in the growth medium on 35-mm collagen-coated dishes until subconfluency. After the culture medium was changed to DMEM with 2% FBS for 24 hours, the cells were treated with test compounds or vehicle (0.1% dimethylsulfoxide) for the indicated period. The cells were harvested and homogenized in PBS containing 1 mmol/L EDTA. eNOS activity was measured as the conversion of radiolabeled L-arginine to L-citrulline using NOS Quantitative Assay Kit (Bioxytech, OXIS International). Incubation in the presence of the eNOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) (1 mmol/L) served as negative controls.
Western Blot Analysis
BAECs grown on 35-mm collagen-coated dishes were treated for test compounds or vehicle in DMEM with 2% FBS for the indicated periods. The cells were scraped in lysis buffer with protease inhibitor cocktail tablet (complete Mini; Roche), 200 μmol/L NaF, 200 μmol/L Na3VO4, 1 μmol/L dithiothreitol, and 200 μmol/L phenylmethylsulfonyl fluoride, and then sonicated briefly. After being boiled for 2 minutes, the samples were centrifuged at 15 000 rpm for 5 minutes and then analyzed by SDS-PAGE. The gels were transferred to polyvinylidine difluoride (PVDF) membranes (Bio-Rad) by blotting at 100 V for 2 hours. After incubation for 1 hour in blocking buffer (5% skim milk powder in TBS-T ), the membranes were incubated with primary antibody overnight at 4°C. After washing with TBS-T, the membranes were incubated with second antibody at room temperature for 1 hour. The membranes were then washed with TBS-T, and signals were visualized by chemiluminescence (Amersham) and exposed to x-ray films (Fujifilm).
Northern Blot Analysis
BAECs grown on 10-cm collagen-coated dishes were treated for test compounds or vehicle in DMEM with 2% FBS for the indicated periods. Total RNA extracted by the acid guanidinium thiocyanate-phenol-chloroform method was electrophoresed in 1% agarose-5% formaldehyde gels. The gels were transferred to nylon membranes (Hybond N+, Amersham), and the membranes were hybridized at 68°C with 32P-labeled bovine eNOS cDNA probe or GAPDH cDNA probe using Perfect hybridization buffer (Toyobo). After the hybridization, the filters were washed two times in 2xSSC and 0.1% SDS at 60°C for 10 minutes, followed by washing in 0.1xSSC and 0.1% SDS at 60°C for 30 minutes. The membranes were then dried and exposed to x-ray films.
Transient Transfection and Luciferase Reporter Assay
To examine the effect of test compounds on eNOS promoter activity, BAECs were transiently transfected with an eNOS reporter construct. The eNOS reporter consists of 5'-flanking region (-1600 to +26) of the human eNOS gene and firefly luciferase. BAECs on 24-well collagen-coated dishes were transfected with the reporter plasmids (1 μg) together with seapansy luciferase control plasmid (0.05 μg; Tokyo Beanet) using SuperFect Transfection Reagent (QIAGEN). Two hours after the transfection, the cells were treated for 24 hours with test compounds or vehicle. The cell lysates were assayed for each luciferase activity in Lumat LB9501 luminometer (Berthold System).
eNOS mRNA Stability Assay
Subconfluent BAECs on 10-cm collagen coated dishes were treated for the indicated periods with fenofibrate or vehicle in the presence of 2.5 μg/mL actinomycin D in DMEM with 2% FBS. Northern blot analyses for eNOS mRNA and GAPDH mRNA were performed, as described.
Statistics
All values represent mean±SD. The data were analyzed by ANOVA, and the Bonferroni method was used to estimate the level of significance of differences between means. P<0.05 was considered statistically significant.
Results
Effects of Fenofibrate on eNOS Activity
First, we investigated whether fenofibrate alters eNOS enzymatic activity in lysates of BAECs. As shown in Figure 1A, fenofibrate treatment for 48 hours increased eNOS activity in a concentration-dependent manner: At concentrations of 10 μmol/L or more, fenofibrate treatment caused a significant increase in eNOS activity. There was no increase in eNOS activity by fenofibrate treatment within 1 hour, and the fenofibrate-stimulated induction of eNOS activity was observed 24 hours after stimulation (Figure 1B).
Figure 1. Fenofibrate increases eNOS activity in BAECs. A, BAECs were treated for 48 hours with increasing concentrations of fenofibrate. B, BAECs were treated for the indicated periods with 50 μmol/L fenofibrate. Cell lysates were harvested for determination of eNOS activity. Data are mean±SD in three experiments. cont indicates control; Feno, fenofibrate. *P<0.005, **P<0.0001 vs control, by ANOVA.
Effects of Fenofibrate on eNOS Protein Expression
Treatment of BAECs with fenofibrate for 48 hours demonstrated a concentration-dependent increase in eNOS protein levels as measured by Western blot analysis (Figure 2 A and 2B). Densitometric analysis indicated that there was a significant increase in eNOS to ?-actin ratios after fenofibrate treatment at concentrations of 10 and 50 μmol/L. The significant increase in eNOS protein levels was observed 12 hours after treatment and lasted for 48 hours (Figure 2C and 2D).
Figure 2. Fenofibrate increases eNOS protein levels in BAECs, as demonstrated by Western blot analyses. A and B, BAECs were treated for 48 hours with increasing concentrations of fenofibrate. C and D, BAECs were treated for the indicated period with 50 μmol/L fenofibrate. Representative blots are illustrated in A and C. The densitometric readings as percent control of eNOS relative to ?-actin levels are shown in B and D. Data are mean±SD in three experiments. cont indicates control; Feno, fenofibrate. *P<0.005, **P<0.0001 vs control, by ANOVA.
As shown in Figure 3, treatment of BAECs with 50 μmol/L bezafibrate as well as 50 μmol/L WY14643 for 48 hours also caused a significant increase in eNOS protein levels, whereas 50 μmol/L rosiglitazone elicited no change. The simultaneous treatment of BAECs with RU486 (10 μmol/L) resulted in the inhibition of fenofibrate (50 μmol/L)-induced increase in eNOS protein levels (Figure 4).
Figure 3. Fenofibrate, bezafibrate, and WY14643, but not rosiglitazone, increase eNOS protein levels in BAECs, as demonstrated by Western blot analyses. BAECs were treated for 48 hours with fenofibrate (10 or 50 μmol/L), bezafibrate (10 or 50 μmol/L), rosiglitazone (50 μmol/L), or WY14643 (50 μmol/L). Representative blots are illustrated in A. The densitometric readings as percent control of eNOS relative to ?-actin levels are shown in B. Data are mean±SD in three experiments. cont indicates control; Feno, fenofibrate; Beza, bezafibrate; Rosi, rosiglitazone; WY, WY14643. *P<0.005, **P<0.0001 vs control, by ANOVA.
Figure 4. RU486 antagonizes fenofibrate-induced increase in eNOS protein levels in BAECs, as demonstrated by Western blot analyses. BAECs were treated for 48 hours with 50 μmol/L fenofibrate together with or without 10 μmol/L RU486. Representative blots are illustrated in A. The densitometric readings as percent control of eNOS relative to ?-actin levels are shown in B. Data are mean±SD in three experiments. cont indicates control; Feno, fenofibrate. *P<0.0001 vs Feno alone, by ANOVA.
Effects of Fenofibrate on eNOS mRNA Expression
Northern blot analysis demonstrated that treatment with fenofibrate for 24 hours resulted in a concentration-dependent increase in eNOS mRNA levels (Figure 5A). Densitometric scan revealed that eNOS mRNA relative to GAPDH mRNA significantly increased at concentrations of 5 μmol/L or more: it reached 1.9-fold by the treatment with 50 μmol/L fenofibrate (Figure 5B). Significant increase in eNOS mRNA levels was observed after 6 hours, and subsequently there was a gradual decrease of eNOS mRNA levels (Figure 5C and 5D).
Figure 5. Fenofibrate increases eNOS mRNA levels in BAECs, as demonstrated by Northern blot analyses. A and B, BAECs were treated for 24 hours with increasing concentrations of fenofibrate. C and D, BAECs were treated for the indicated periods with 50 μmol/L fenofibrate. Representative blots are illustrated in A and C. The densitometric readings as percent control of eNOS mRNA relative to GAPDH mRNA levels are shown in B and D. Data are mean±SD in three experiments. cont indicates control; Feno, fenofibrate. *P<0.0001 vs control, by ANOVA.
Effects of Fenofibrate on eNOS Promoter Activity and eNOS mRNA Stability
To investigate whether or not fenofibrate increases eNOS mRNA levels at transcription levels, we performed transient transfection assay using eNOS promoter fragment (Figure 6A). PMA, used as a positive control, increased eNOS promoter activity by 4.0-fold compared with that in unstimulated cells. Fenofibrate failed to increase eNOS promoter activity.
Figure 6. Fenofibrate fails to increase eNOS promoter activity (A). It increases half-life of eNOS mRNA (B). A, Two hours after transfection with -1600 to +26 of human eNOS gene-based luciferase reporter construct, BAECs were treated for 24 hours with 50 μmol/L fenofibrate or 100 nM PMA. Luciferase activity was adjusted for control reporter activity. Data are mean±SD in triplicated assays typical of three separate experiments. B, BAECs were treated with or without 50 μmol/L fenofibrate up to 15 hours in the presence of actinomycin D (2.5 μg/mL). Northern blot analyses were performed. The densitometric readings as percent of initial eNOS mRNA relative to GAPDH mRNA levels are shown. Data are mean±SD in three experiments. cont indicates control; Feno, fenofibrate. *P<0.001, **P<0.0005 vs control, by ANOVA.
Next, we studied the effects of fenofibrate on eNOS mRNA stability after stopping the transcription with actinomycin D. The half-life of eNOS mRNA relative to GAPDH mRNA levels was about 24 hours in control, and it increased to about 110 hours by treatment with 50 μmol/L fenofibrate (Figure 6B).
Discussion
The PPAR activators fibrates are shown to slow atherosclerosis progression and reduce the number of events of coronary heart diseases.3–5 Such effects may be attributable at least in part to their effects on lipoprotein abnormalities, which are mainly exerted by PPAR expressed in the liver. Several studies9,10,17,18 have demonstrated that PPAR is also expressed in vascular endothelial cells. Recently, direct roles of fibrates in vascular endothelial cells have become evident, clarifying the inhibitory effects of the PPAR activators on the expression of VCAM-1, IL-6, and endothelin-1.8–10 IL-6 is known to control macrophage and T cell activation as well as vascular smooth muscle cell proliferation,19,20 and has been detected in human and rabbit atherosclerotic regions.21,22 VCAM-1 plays an important role in mediating mononuclear leukocyte-selective adhesion to vascular endothelium, which may be involved in the initial steps of atherosclerotic process.23 Endothelin-1 is a potent vasoconstrictor peptide and inducer of vascular smooth muscle cell proliferation.24,25 Thus, all these molecules are known to be involved in the atherosclerotic process, and suppression of their expression may also be attributable partly to the antiatherogenic effects of PPAR activators.
Endothelium-derived NO is a potent chemical mediator with antiatherogenic properties, such as stimulation of vasorelaxation and repression of endothelial leukocyte adhesion molecules, platelet aggregation, and smooth muscle cell proliferation.16,26,27 To date, it is unknown whether PPAR activators can directly modulate eNOS activity and its expression, which mediates endothelial NO production. Our study clearly demonstrates that fenofibrate upregulated eNOS protein levels in cultured vascular endothelial cells. This effect of fenofibrate was observed at concentrations at 10 μmol/L or more, which are near to plasma concentrations of its active metabolite fenofibric acid found in humans administered.28 In addition, such concentrations corresponded closely to the range of activation of PPAR by fenofibrate, although this compound can also activate PPAR with approximately 10-fold lower selectivity than PPAR.29,30 WY14643, a selective PPAR activator,30 and bezafibrate, a hypolipidemic drug that potentially activates three types of PPAR (PPAR, -, and -),30,31 also increased eNOS protein expression. By contrast, rosiglitazone, a specific ligand for PPAR,32 failed to increase eNOS protein levels. In addition, RU486, which has been shown to have a potential to antagonize the inhibitory effect of PPAR on IL-6 production probably via interference with nuclear translocation of PPAR,33 inhibited the fenofibrate-induced upregulation of eNOS expression. The sum total of these observations suggests that fenofibrate-induced upregulation of eNOS protein expression may be mediated through PPAR.
We demonstrated that eNOS mRNA levels increased after the treatment of vascular endothelial cells with fenofibrate, which is parallel with the increase in protein levels and enzymatic activity of eNOS. Thus, the effect of fenofibrate is primarily caused by the elevation of steady state levels of eNOS mRNA. It is known that eNOS activity is regulated by genomic mechanisms as well as nongenomic mechanisms. The latter mechanisms imply activation by phosphorylation of eNOS by the protein kinase Akt/protein kinase B (PKB).34,35 In our experiments, eNOS activity could not increase so rapidly (1 hour) after the fenofibrate treatment, indicating that PPAR does not exert posttranslational modification of eNOS activity. This seems to be in contrast with cases of other nuclear receptors such as estrogen receptor36 and glucocorticoid receptor,37 both of which are capable of stimulating phosphatidylinositol 3-kinase (PI3-K) and Akt/PKB. Simoncini et al36 have shown that WY14643 failed to activate PI3-K activity in PPAR immunoprecipitates. However, it is not possible from our results to determine the effect of fenofibrate on phosphorylation of eNOS. Further studies will be needed to clarify this issue.
Analysis of the human eNOS promoter sequence (-1600 to +22 nucleotides) did not reveal the presence of any discernible PPAR response elements,38 suggesting that PPAR may not directly interact with eNOS promoter region. In fact, transient transfection experiments of the eNOS promoter construct showed that fenofibrate could not elevate its promoter activity. mRNA stability assays using the transcriptional inhibitor actinomycin D revealed that fenofibrate increased the half-life of eNOS mRNA, suggesting that fenofibrate performs the novel action of stabilizing mRNA for eNOS. The precise mechanism of fenofibrate-mediated mRNA stabilization is unknown. In this relation, it has been postulated that estrogens stabilize mammalian mRNAs, requiring specific sequences of the mRNA and the presence of estrogen receptor.39 Similar mechanisms may operate in the stabilizing effect of PPAR on eNOS mRNA.
The PPAR activators glitazones are also shown to improve vascular and endothelial function.40 In our experiments, rosiglitazone failed to upregulate eNOS protein levels. Recently, PPAR ligands have been shown to increase NO release from vascular endothelial cells without altering eNOS mRNA levels, probably through a transcriptional mechanism unrelated to eNOS expression.41 Together with these results, our findings show that PPAR and PPAR may increase NO production in endothelium by different mechanisms.
Tabernero et al42 have shown that fenofibrate improves NO-mediated vasodilatation in the aorta and in the mesenteric vascular bed, which cannot be explained by an increase in eNOS expression. In addition, Deplanque et al43 have demonstrated that fenofibrate reduces susceptibility to stroke in apolipoprotein E-deficient mice and decreases infarct size volume in mice. This neuroprotective effect is partly associated with an improvement in middle cerebral artery sensitivity to endothelium-dependent relaxation, which is unrelated to an increase in eNOS expression. Thus, the effects of fenofibrate on eNOS expression in these mouse models are not the same as those observed in our study. These mouse models may not always reflect the direct effect of fenofibrate on endothelial cells.
Diabetes Atherosclerosis Intervention Study (DAIS)5 as well as Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)3,4 suggest that treatment with fenofibrate or bezafibrate reduces the progression of coronary artery disease. It is thought that such effects are related, at least partly, to the correction of lipoprotein abnormalities. Mice with targeted disruption of eNOS revealed that eNOS is a very important molecule that plays beneficial roles in cardiovascular disease.44 Therefore, upregulation of eNOS expression and its activity by fenofibrate as well as bezafibrate may also attribute to these drugs a mediated inhibition of the atherosclerosis progression. The expression of eNOS and endothelin-1 is known to be coordinately regulated in diverse pharmacological and experimental conditions.45,46 Since PPAR agonists have the potential to inhibit endothelin-1 expression,10 our results may give another example of the coordinated regulation between eNOS and endothelin-1 systems. These effects might explain the vasodilator function of PPAR agonists.13,14
Acknowledgments
We thank Dr Yasuko Kureishi (Mie University) for providing us bovine eNOS cDNA probe and Dr Masafumi Nakayama (Kumamoto University) for providing human eNOS reporter construct. This work was supported in part by a grant-in-aid for scientific research from the Ministry of Education, Science, Sports, and Culture of Japan (to S. Kasayama).
References
Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000; 405: 421–424.
Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998; 98: 2088–2093.
Ericsson CG, Nilsson J, Grip L, Svane B, Hamsten A. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial ). Am J Cardiol. 1997; 80: 1125–1129.
Ruotolo G, Ericsson CG, Tettamanti C, Karpe F, Grip L, Svane B, Nilsson J, de Faire U, Hamsten A. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol. 1998; 32: 1648–1656.
Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001; 357: 905–910.
Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-B and AP-1. J Biol Chem. 1999; 274: 32048–32054.
Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPAR but not by PPAR activators. Nature. 1998; 393: 790–793.
Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPAR activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999; 99: 3125–3131.
Xu X, Otsuki M, Saito H, Sumitani S, Yamamoto H, Asanuma N, Kouhara H, Kasayama S. PPAR and GR differentially down-regulate the expression of nuclear factor-B-responsive genes in vascular endothelial cells. Endocrinology. 2001; 142: 3332–3339.
Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, Staels B. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 1999; 85: 394–402.
Neve BP, Corseaux D, Chinetti G, Zawadzki C, Fruchart JC, Duriez P, Staels B, Jude B. PPAR agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation. 2001; 103: 207–212.
Playford DA, Watts GF, Best JD, Burke V. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol. 2002; 90: 1254–1257.
Capell WH, DeSouza CA, Poirier P, Bell ML, Stauffer BL, Weil KM, Hernandez TL, Eckel RH. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2003; 23: 307–313.
Loscalzo J. Nitric oxide and vascular tone. N Engl J Med. 1995; 333: 251–253.
De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr., Shin WS, Liao JK. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995; 96: 60–68.
Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Luscher TF. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995; 92: 1314–1319.
Inoue I, Shino K, Noji S, Awata T, Katayama S. Expression of peroxisome proliferator-activated receptor (PPAR) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun. 1998; 246: 370–374.
Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem. 1999; 274: 9116–9121.
Akira S, Kishimoto T. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Review. 1992; 127: 25–50.
Nabata T, Morimoto S, Koh E, Shiraishi T, Ogihara T. Interleukin-6 stimulates c-myc expression and proliferation of cultured vascular smooth muscle cells. Biochem Int. 1990; 20: 445–454.
Ikeda U, Ikeda M, Seino Y, Takahashi M, Kano S, Shimada K. Interleukin 6 gene transcripts are expressed in atherosclerotic legions of genetically hyperlipidemic rabbits. Atherosclerosis. 1992; 92: 213–218.
Seino Y, Ikeda U, Ikeda M, Yamamoto K, Misawa Y, Hasegawa T, Kano S, Shimada K. Interleukin 6 gene transcripts are expressed in human atherosclerotic legions. Cytokine. 1994; 6: 87–91.
Bevilacqua MP, Nelson RM, Mannori G, Cecconi O. Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med. 1994; 45: 361–378.
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 323: 411–415.
Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett. 1988; 238: 249–252.
Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993; 329: 2002–2012.
Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, Kleinert H. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension. 1994; 23: 1121–1131.
Adkins JC, Faulds D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs. 1997; 54: 615–633.
Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B, Auwerx J. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest. 1995; 96: 741–750.
Krey G, Braissant O, L’Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 1997; 11: 779–791.
Brown PJ, Winegar DA, Plunket KD, Moore LB, Lewis MC, Wilson JG, Sundseth SS, Koble CS, Wu Z, Chapman JM, Lehmann JM, Kliewer SA, Willson TM. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPAR agonist with potent lipid-lowering activity. J Med Chem. 1999; 42: 3785–3788.
Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ, Haigh D, Hindley RM, Holder JC, Kallender H, Latter AJ, Lawrie KW, Mossakowska D, Murphy GJ, Roxbee Cox L, Smith SA. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther. 1998; 284: 751–759.
Xu X, Otsuki M, Sumitani S, Saito H, Kouhara H, Kasayama S. RU486 antagonizes the inhibitory effect of peroxisome proliferators-activated receptor on interleukin-6 production in vascular endothelial cells. J Steroid Biochem Molec Biol. 2002; 81: 141–146.
Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999; 399: 597–601.
Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999; 399: 601–605.
Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000; 407: 538–541.
Hafezi-Moghadam A, Simoncini T, Yang E, Limbourg FP, Plumier JC, Rebsamen MC, Hsieh CM, Chui DS, Thomas KL, Prorock AJ, Laubach VE, Moskowitz MA, French BA, Ley K, Liao JK. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nature Med. 2002; 8: 473–479.
Zhang R, Min W, Sessa WC. Functional analysis of the human endothelial nitric oxide synthase promoter. Sp1 and GATA factors are necessary for basal transcription in endothelial cells. J Biol Chem. 1995; 270: 15320–15326.
Dodson RE, Shapiro DJ. An estrogen-inducible protein binds specifically to a sequence in the 3' untranslated region of estrogen-stabilized vitellogenin mRNA. Mol Cell Biol. 1994; 14: 3130–3138.
Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in zucker fatty rats. Diabetes. 1999; 48: 1448–1453.
Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol. 2003; 23: 52–57.
Tabernero A, Schoonjans K, Jesel L, Carpusca I, Auwerx J, Andriantsitohaina R. Activation of the peroxisome proliferator-activated receptor protects against myocardial ischaemic injury and improves endothelial vasodilatation. BMC Pharmacol. 2002; 2: 10.
Deplanque D, Gele P, Petrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, Cecchelli R, Staels B, Duriez P, Bordet R. Peroxisome proliferator-activated receptor- activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci. 2003; 16: 6264–6271.
Moroi M, Zhang L, Yasuda T, Virmani R, Gold HK, Fishman MC, Huang PL. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest. 1998; 101: 1225–1232.
Flowers MA, Wang Y, Stewart RJ, Patel B, Marsden PA. Reciprocal regulation of endothelin-1 and endothelial constitutive NOS in proliferating endothelial cells. Am J Physiol. 1995; 269: H1988–H1997.
Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998; 101: 2711–2719.(Kayoko Goya; Satoru Sumit)